Le Lézard
Classified in: Health, Business
Subjects: PDT, SCZ

Bipartisan, Bicameral PACE Part D Choice Act Would Reduce Part D Costs and Increase Access for Medicare Beneficiaries to Innovative Programs of All Inclusive Care for the Elderly


WASHINGTON, May 19, 2023 /PRNewswire/ -- This week, U.S. Representatives Brad Wenstrup, MD (R-OH) and Earl Blumenauer (D-OR3) and U.S. Senators Tom Carper (D-DE) and Bill Cassidy, MD (R-LA) introduced The PACE Part D Choice Act, which would eliminate a significant financial disincentive for Medicare-only beneficiaries to enroll in Programs of All-Inclusive Care for the Elderly or PACE.

"Everyone deserves a fair choice when it comes to health care and we must ensure that access to this choice is affordable," said Senator Tom Carper (D-Del.). "The PACE Part D Choice Act would give seniors the option to choose a cost-efficient plan that will provide them with the care they need."

Although many PACE participants are eligible for Medicare and Medicaid, for those who do not qualify for Medicaid, their average monthly Part D plan premium costs of $983.66 in 2023 are considerably higher?more than 20 times higher, than the $43 average monthly cost of a marketplace plan. The PACE Part D Choice Act would increase access to PACE for Medicare-only beneficiaries by enabling them to choose between the PACE Part D plan or a marketplace Part D plan, which is likely to have fewer total costs such as lower premiums and related deductible and coinsurance amounts. The policy solution in the legislation has been cited by non-partisan think tanks, including in a Bipartisan Policy Center report, highlighted as a notable way to address the lack of care options outside of nursing homes for our nation's fast-growing older  population.

"PACE patients should have the same access to lower premiums and affordable prescription drugs as those in other Medicare programs," said Dr. Cassidy. "This will lead to better health outcomes for seniors with chronic illness."

"PACE is a proven model of care for older adults, and it has continued to demonstrate its benefits even more profoundly during and after the pandemic," said Shawn Bloom, President and CEO of the National PACE Association. "But widespread enrollment in PACE for the millions of Medicare-only beneficiaries who could benefit faces a significant financial obstacle --the high Part D premium cost. NPA strongly urges Congress to pass this bill quickly so that many more older adults and their families can be served by PACE and receive the care they need in their homes and communities." 

Currently, 150 PACE programs operate at least 309 PACE centers in 32 states and the District of Columbia, serving more than 64,000 participants. However, if barriers to joining PACE were eliminated, including the high Part D premium, many millions more eligible seniors could be taking advantage of the benefits that PACE offers.

SOURCE National PACE Association


These press releases may also interest you

at 16:10
Prothena Corporation plc , a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2024 and provided...

at 16:10
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported financial results for the three months ended...

at 16:10
QuidelOrtho Corporation (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs, and transfusion medicine, today announced financial results for the first...

at 16:10
Acadia Pharmaceuticals Inc. today announced its financial results for the first quarter ended March 31, 2024. "In the first quarter of 2024, Acadia delivered net product sales of $205.8 million, representing 74% revenue growth year over year,...

at 16:10
Zai Lab Limited today announced financial results for the first quarter of 2024, along with recent product highlights and corporate updates. "Our first quarter results demonstrate strong commercial execution and pipeline progress across our...

at 16:10
ChromaDex Corp. today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights Total net sales were $22.2 million, with $17.4 million from Tru Niagen®. Solid gross margin of...



News published on and distributed by: